Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2024-09-06 20:32 Tx date 2024-09-03 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+100,000 vol |
100,000 | |
Filed 2024-09-06 20:30 Tx date 2024-09-03 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$25,000
+100,000 vol $0.25 each |
384,728 | |
Filed 2024-07-29 11:30 Tx date 2024-07-26 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+360,000 vol |
570,000 | |
Filed 2023-08-18 11:28 Tx date 2023-08-15 |
$ONC
Oncolytics Biotech Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$82,800
+30,000 vol $2.76 each |
75,000 | |
Filed 2023-05-05 23:34 Tx date 2023-04-25 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+210,000 vol |
210,000 | |
Filed 2022-09-26 09:18 Tx date 2022-09-22 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$3,500
+10,000 vol $0.35 each |
284,728 | |
Filed 2022-09-26 09:13 Tx date 2022-09-22 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
$-3,500
-10,000 vol $0.35 each |
0 | |
Filed 2022-06-23 10:00 Tx date 2022-06-20 |
$ONC
Oncolytics Biotech Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$51,299
+45,000 vol $1.14 each |
45,000 | |
Filed 2022-06-23 09:57 Tx date 2022-06-16 |
$ONC
Oncolytics Biotech Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2022-02-08 19:29 Tx date 2022-02-08 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
99 - Correction of information
|
-475,000 vol |
60,649 | |
Filed 2022-02-08 19:26 Tx date 2022-02-08 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
99 - Correction of information
|
-73,150 vol |
36,259 | |
Filed 2022-02-08 19:23 Tx date 2022-01-03 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
56 - Grant of rights
|
$60,047
+16,773 vol $3.58 each |
109,409 | |
Filed 2022-02-08 19:15 Tx date 2021-01-01 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
56 - Grant of rights
|
$62,004
+7,534 vol $8.23 each |
92,636 | |
Filed 2022-02-08 19:13 Tx date 2021-01-01 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
11 - Acquisition or disposition carried out privately
|
$62,004
+7,534 vol $8.23 each |
||
Filed 2021-01-05 19:38 Tx date 2021-01-01 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
11 - Acquisition or disposition carried out privately
|
$63,741
+7,745 vol $8.23 each |
||
Filed 2021-12-16 21:36 Tx date 2021-12-09 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Rights Deferred Share Units
56 - Grant of rights
|
+260,000 vol |
1,285,001 | |
Filed 2021-07-23 20:51 Tx date 2021-07-15 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$34,190
+9,393 vol $3.64 each |
535,649 | |
Filed 2021-07-20 17:49 Tx date 2021-07-15 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$34,190
+9,393 vol $3.64 each |
||
Filed 2021-07-20 17:49 Tx date 2021-07-15 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$34,190
+9,393 vol $3.64 each |
535,649 | |
Filed 2021-02-08 11:15 Tx date 2021-02-08 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
+50,000 vol |
274,728 | |
Filed 2021-02-08 11:14 Tx date 2021-02-08 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
-50,000 vol |
10,000 | |
Filed 2021-01-12 12:21 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-134,270.9865
-8,505 vol $15.79 each |
0 | |
Filed 2021-01-12 12:19 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$78,246
+8,505 vol $9.20 each |
8,505 | |
Filed 2021-01-12 12:12 Tx date 2021-01-08 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-78,246
-8,505 vol $9.20 each |
173,492 | |
Filed 2021-01-05 19:38 Tx date 2021-01-01 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
11 - Acquisition or disposition carried out privately
|
$63,741
+7,745 vol $8.23 each |
92,847 | |
Filed 2021-01-04 13:32 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-398,751.45
-26,970 vol $14.79 each |
0 | |
Filed 2021-01-04 13:30 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$224,929
+26,970 vol $8.34 each |
26,970 | |
Filed 2021-01-04 13:29 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-62,836.25
-4,250 vol $14.79 each |
0 | |
Filed 2021-01-04 13:28 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$31,875
+4,250 vol $7.50 each |
4,250 | |
Filed 2021-01-04 13:26 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-224,929.80
-26,970 vol $8.34 each |
181,997 | |
Filed 2021-01-04 13:24 Tx date 2020-12-31 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-31,875
-4,250 vol $7.50 each |
208,967 | |
Filed 2020-12-28 16:34 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+180,000 vol |
287,893 | |
Filed 2020-12-18 20:00 Tx date 2020-12-18 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-827,940.5888
-65,104 vol $12.72 each |
0 | |
Filed 2020-12-18 19:59 Tx date 2020-12-18 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$275,389
+65,104 vol $4.23 each |
65,104 | |
Filed 2020-12-18 19:58 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-160,186.382
-14,162 vol $11.31 each |
0 | |
Filed 2020-12-18 19:57 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$5,381
+14,162 vol $0.38 each |
14,162 | |
Filed 2020-12-18 19:56 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-244,764.98
-21,046 vol $11.63 each |
0 | |
Filed 2020-12-18 19:55 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$7,997
+21,046 vol $0.38 each |
21,046 | |
Filed 2020-12-18 19:53 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-501,159.96
-43,092 vol $11.63 each |
0 | |
Filed 2020-12-18 19:52 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$33,180
+43,092 vol $0.77 each |
43,092 | |
Filed 2020-12-18 19:51 Tx date 2020-12-18 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-275,389.92
-65,104 vol $4.23 each |
213,217 | |
Filed 2020-12-18 19:50 Tx date 2020-12-16 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-5,381.56
-14,162 vol $0.38 each |
278,321 | |
Filed 2020-12-18 19:49 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-7,997.48
-21,046 vol $0.38 each |
292,483 | |
Filed 2020-12-18 19:47 Tx date 2020-12-15 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-33,180.84
-43,092 vol $0.77 each |
313,529 | |
Filed 2020-12-18 19:06 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,255,613.0784
-106,908 vol $11.74 each |
0 | |
Filed 2020-12-18 19:05 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$82,319
+106,908 vol $0.77 each |
106,908 | |
Filed 2020-12-18 19:03 Tx date 2011-08-25 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 18:21 Tx date 2020-12-14 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
51 - Exercise of options
|
$-82,319.16
-106,908 vol $0.77 each |
356,621 | |
Filed 2020-12-18 17:44 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+463,529 vol |
463,529 | |
Filed 2020-12-18 17:42 Tx date 2011-08-25 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 17:40 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-463,529 vol |
107,893 | |
Filed 2020-12-18 17:34 Tx date 2011-08-25 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 17:33 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-463,529 vol |
||
Filed 2020-12-18 16:48 Tx date 2011-08-25 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
463,529 | ||
Filed 2020-12-18 16:48 Tx date 2011-08-25 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Holder: BMO Nesbitt Burns Inc (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2020-12-18 16:44 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-463,529 vol |
||
Filed 2020-12-18 16:44 Tx date 2020-09-29 |
$TRIL
Trillium Therapeutics Inc. |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-463,529 vol |
107,893 | |
Filed 2020-11-13 09:15 Tx date 2018-11-14 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
+50,000 vol |
50,000 | |
Filed 2018-11-15 15:38 Tx date 2018-11-14 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
+50,000 vol |
||
Filed 2020-09-24 13:10 Tx date 2020-09-22 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+10,000 vol |
60,000 | |
Filed 2020-09-24 13:08 Tx date 2020-09-22 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$3,000
+10,000 vol $0.30 each |
224,728 | |
Filed 2020-06-02 17:58 Tx date 2020-06-01 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+13,306 vol |
526,256 | |
Filed 2020-06-02 17:57 Tx date 2020-06-01 |
$DMAC
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
56 - Grant of rights
|
+8,102 vol |
85,102 | |
Filed 2019-11-12 10:38 Tx date 2019-11-07 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$49,400
+130,000 vol $0.38 each |
571,422 | |
Filed 2019-09-18 10:19 Tx date 2019-09-13 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Rights Deferred Share Units
56 - Grant of rights
|
+740,056 vol |
1,025,001 | |
Filed 2019-06-27 11:54 Tx date 2019-06-24 |
$DMA
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+12,950 vol |
512,950 | |
Filed 2019-05-27 12:54 Tx date 2019-05-10 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$115,500
+150,000 vol $0.77 each |
441,422 | |
Filed 2019-03-11 Tx date 2019-02-28 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
-150,000 vol |
0 | |
Filed 2018-12-11 Tx date 2015-10-23 |
$DMA
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-12-11 Tx date 2018-12-11 |
$DMA
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
+2,250 vol |
2,250 | |
Filed 2018-11-15 Tx date 2018-11-14 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Special Warrants
54 - Exercise of warrants
|
$-12,500
-50,000 vol $0.25 each |
0 | |
Filed 2018-11-15 Tx date 2018-11-14 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Warrants
54 - Exercise of warrants
|
+50,000 vol |
50,000 | |
Filed 2018-11-15 Tx date 2018-11-14 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
54 - Exercise of warrants
|
$12,500
+50,000 vol $0.25 each |
214,728 | |
Filed 2018-11-09 Tx date 2018-11-08 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$528,750
+125,000 vol $4.23 each |
291,422 | |
Filed 2018-07-17 Tx date 2018-07-13 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Special Warrants
16 - Acquisition or disposition under a prospectus exemption
|
$12,500
+50,000 vol $0.25 each |
50,000 | |
Filed 2018-07-17 Tx date 2012-04-19 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Special Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-07-12 Tx date 2018-04-17 |
$DMA
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$33,600
+60,000 vol $0.56 each |
500,000 | |
Filed 2018-07-04 Tx date 2018-06-30 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Warrants
55 - Expiration of warrants
|
-40,000 vol |
0 | |
Filed 2017-11-13 Tx date 2017-11-09 |
$TRIL
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$298,045
+24,390 vol $12.22 each |
166,422 | |
Filed 2017-09-14 Tx date 2017-08-14 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Rights Deferred Share Units
56 - Grant of rights
|
+59,945 vol |
284,945 | |
Filed 2017-06-23 Tx date 2017-06-19 |
$DMA
DiaMedica Therapeutics Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
440,000 | |
Filed 2017-04-18 Tx date 2017-04-18 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$8,951
+49,728 vol $0.18 each |
164,728 | |
Filed 2017-04-18 Tx date 2017-04-18 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-8,951.04
-49,728 vol $0.18 each |
150,000 | |
Filed 2017-04-17 Tx date 2017-04-13 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$29,970
+166,500 vol $0.18 each |
281,500 | |
Filed 2017-04-17 Tx date 2017-04-17 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-48.96
-272 vol $0.18 each |
199,728 | |
Filed 2017-04-17 Tx date 2017-04-13 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-29,970
-166,500 vol $0.18 each |
200,000 | |
Filed 2017-04-17 Tx date 2017-04-17 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$48.96
+272 vol $0.18 each |
115,272 | |
Filed 2017-04-17 Tx date 2017-04-17 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-68.00
-272 vol $0.25 each |
115,000 | |
Filed 2017-04-17 Tx date 2017-04-13 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-41,625
-166,500 vol $0.25 each |
115,000 | |
Filed 2017-04-12 Tx date 2017-04-11 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-6,030
-33,500 vol $0.18 each |
366,500 | |
Filed 2017-04-12 Tx date 2017-04-11 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-8,375
-33,500 vol $0.25 each |
115,000 | |
Filed 2017-04-12 Tx date 2017-04-11 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$6,030
+33,500 vol $0.18 each |
148,500 | |
Filed 2016-12-02 Tx date 2015-10-23 |
$DMA
DiaMedica Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-02 Tx date 2016-11-28 |
$DMA
DiaMedica Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
340,000 | |
Filed 2016-12-02 Tx date 2016-11-28 |
$DMA
DiaMedica Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Deferred Share Units
56 - Grant of rights
|
$14,630
+77,000 vol $0.19 each |
77,000 | |
Filed 2016-11-10 Tx date 2016-08-25 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
52 - Expiration of options
|
$-12,510
-417 vol $30.00 each |
127,766 | |
Filed 2016-11-10 Tx date 2016-11-09 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$131,247
+14,266 vol $9.20 each |
142,032 | |
Filed 2016-07-06 Tx date 2016-06-30 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+40,000 vol |
40,000 | |
Filed 2016-07-06 Tx date 2012-04-19 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
75,000 | ||
Filed 2016-07-06 Tx date 2012-04-19 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-07-06 Tx date 2016-06-30 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$10,000
+40,000 vol $0.25 each |
115,000 | |
Filed 2016-05-30 Tx date 2016-05-27 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+30,171 vol |
128,183 | |
Filed 2016-03-14 Tx date 2016-03-14 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Rights Deferred Share Units
56 - Grant of rights
|
+100,000 vol |
225,000 | |
Filed 2015-12-15 Tx date 2015-10-23 |
$DMA
DiaMedica Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-12-15 Tx date 2015-12-01 |
$DMA
DiaMedica Inc. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$36,000
+240,000 vol $0.15 each |
240,000 | |
Filed 2015-11-20 Tx date 2015-11-19 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+30,171 vol |
98,012 | |
Filed 2015-06-29 Tx date 2015-06-25 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Rights Deferred Share Units
56 - Grant of rights
|
+125,000 vol |
125,000 | |
Filed 2015-06-29 Tx date 2012-04-19 |
$SVA
Sernova Corp. |
Parsons, James Todd
4 - Director of Issuer
Direct Ownership
|
Rights Deferred Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+4,250 vol |
1,899,875 | |
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-127,514 vol |
1,895,625 | |
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+417 vol |
2,023,139 | |
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-12,500 vol |
2,022,722 | |
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-1,086,119 vol |
813,756 | |
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+36,204 vol |
849,960 | |
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-809,089 vol |
40,871 | |
Filed 2015-05-22 Tx date 2014-11-14 |
$TR
Trillium Therapeutics Inc. (formerly Stem Cell Therapeutics Corp.) |
Parsons, James Todd
5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+26,970 vol |
67,841 |